Rexulti - Otsuka Pharmaceutical Co., Ltd.

Articles about Otsuka Pharmaceutical Co., Ltd.

REXULTI® (brexpiprazole), SZ

Brexpiprazole - Mechanism of Action and Clinical Application

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer's Dementia

FDA Approves New Schizophrenia, Depression Drug Brexpiprazole - Psychiatry Advisor

11.22.23 Otsuka in FDA doghouse over Rexulti marketing claims; Madrigal nabs Dupixent launch lead as new CCO - Questex

REXULTI - Otsuka Pharmaceutical Co., Ltd. Trademark Registration

Home Otsuka US

Otsuka America Pharmaceutical 59148003813 - McKesson Medical-Surgical

REXULTI® (brexpiprazole) Savings & Cost Information

REXULTI BREXPIPRAZOLE - Otsuka Pharmaceutical Co., Inc. Trademark Registration

alembic pharmaceuticals: Alembic Pharma gets USFDA nod to market generic antidepressant drug - The Economic Times

Agitation in Alzheimer's: Rexulti® Makes Meaningful Improvements

FDA approves treatment for agitation associated with dementia created by Princeton-based Otsuka